Camden National Corporation’s Edwards Lifesciences EW Stock Holding History

Camden National Corporation’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$6.52M	Buy	+77,973	New	+$6.59M	1.3%	37

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Camden National Corporation's EW Position: Q1 2021 in Review

Camden National Corporation opened a new position in Edwards Lifesciences (EW) in Q1 2021: 77,973 shares worth $6.52M. The stake represents 1.3% of the portfolio and ranks #37 among its holdings.

1,143 funds tracked by Wall St. Rank hold EW as of Q1 2021.

Camden National Corporation held 77,973 shares of Edwards Lifesciences worth $6.52M as of Q1 2021.
Edwards Lifesciences was a new Camden National Corporation position in Q1 2021.
Edwards Lifesciences made up 1.3% of Camden National Corporation's portfolio in Q1 2021, its #37 holding.
1,143 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2021.

Based on Camden National Corporation's 13F filing for Q1 2021, filed 12 May 2021.